RxDoctor Payments DataLook up a doctor →

Leo Polosajian, MD

Clinical Cardiac Electrophysiology · Reseda, CANPI 1174664783

Payments from drug & device makers

$262,984in general payments, 2019–2025

Across 1,421 payments — averaging $185.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$117K
  • Abbott$110K
  • AstraZeneca$13K
  • Novartis$4K
  • Medtronic$2K
  • Amgen$2K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$6,3874%
  • Speaking & faculty fees$12,0757%
  • Travel & lodging$3,1782%
  • Food & beverage$33,23020%
  • Education$3630%
  • Other$113,75067%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Angiodynamics, Inc.23$116,849
Abbott315$109,676
AstraZeneca48$12,812
Novartis127$3,598
Medtronic(2 entities)67$2,109
Amgen93$1,869
Cvrx, Inc.23$1,681
Bayer75$1,550
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)96$1,339
Boston Scientific49$1,333
Pfizer78$1,034
Boehringer Ingelheim37$868
Bard Peripheral Vascular, Inc.32$808
Merck31$802
Sanofi-aventis U.S. LLC31$718
Johnson & Johnson48$668
Amarin Pharma, Inc.28$527
Edwards Lifesciences7$420
E.r. Squibb & Sons, L.L.C.35$350
Atricure, Inc.5$327
Actelion Pharmaceuticals US, Inc.15$301
Novo Nordisk13$283
Kiniksa Pharmaceuticals, Ltd.11$280
Kiniksa Pharmaceuticals International, PLC9$242
Lexicon Pharmaceuticals, Inc.11$214
Esperion Therapeutics, Inc.9$214
Impulse Dynamics (USA) Inc.4$211
Alnylam Pharmaceuticals Inc.9$177
Scpharmaceuticals Inc.7$163
Heartflow, Inc.8$161
Gilead16$143
Biotronik Inc.8$128
Cordis US CORP.6$116
Philips North America LLC4$85
Organogenesis Inc.4$83
Cardiva Medical, Inc.1$82
Kestra Medical Technology Services, Inc.3$78
Baxter Healthcare3$70
Terumo Medical Corporation3$63
Tactile Systems Technology Inc3$51
Arbor Pharmaceuticals, Inc.3$50
Kowa Pharmaceuticals America, Inc.2$43
Cathworks, Inc.2$41
Irhythm Technologies, Inc.1$36
Venclose Inc.1$32
Convatec Inc.1$30
Acist Medical Systems, Inc.1$27
AbbVie1$26
Avinger Inc.1$25
Bardy Diagnostics, Inc.2$24
Cagent Vascular Inc1$21
Regeneron Healthcare Solutions, Inc.1$19
Biom'up France SAS1$18
Sun Pharmaceutical Industries Inc.1$17
G Medical Diagnostic Services, Inc.1$16
Micro-tech Endoscopy USA, Inc.1$16
Biom'up SA1$16
Preventice Services, LLC1$16
Cook Medical LLC1$13
Amryt Pharma Holdings Ltd1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$262,984 in reported general payments places this provider in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$7,660,916
Medicare patients
1,651
Services billed
38,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,409$1,124,487
EntrestoSacubitril/Valsartan1,163$968,275
Repatha SureclickEvolocumab666$393,021
FarxigaDapagliflozin Propanediol332$292,507
AdempasRiociguat14$193,695
XareltoRivaroxaban193$181,514
JardianceEmpagliflozin109$99,858
Praluent PenAlirocumab164$93,985
BrilintaTicagrelor170$93,414
OzempicSemaglutide68$63,923
JanuviaSitagliptin Phosphate91$61,141
MultaqDronedarone Hcl52$54,021
DapagliflozinDapagliflozin Propanediol93$53,229
VerquvoVericiguat54$41,786
Fenofibrate239$33,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,034$1,124,4871,409 claims
NovartisEntresto$3,598$968,2751,163 claims
AstraZenecaFarxiga, Brilinta, Nexium$12,812$394,584523 claims
BayerAdempas$1,550$193,69514 claims
Johnson & JohnsonXarelto$668$181,514193 claims
MerckJanuvia, Verquvo, Janumet$802$121,406178 claims
Boehringer IngelheimJardiance, Jentadueto Xr$868$106,201121 claims
Novo NordiskOzempic$283$63,92368 claims
Sanofi-aventis U.S. LLCMultaq$718$54,02152 claims
AbbVieLinzess$26$14,81820 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$50$6,91121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →